Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins
- PMID: 10410676
- DOI: 10.1023/b:scam.0000007124.19463.e5
Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins
Abstract
Huntington's disease (HD) is caused by an expanded CAG trinucleotide repeat encoding a tract of consecutive glutamines near the amino terminus of huntingtin, a large protein of unknown function. It has been proposed that the expanded polyglutamine stretch confers a new property on huntingtin and thereby causes cell and region-specific neurodegeneration. Genotype-phenotype correlations predict that this novel property appears above a threshold length (approximately 38 glutamines), becomes progressively more evident with increasing polyglutamine length, is completely dominant over normal huntingtin and is not appreciably worsened by a double genetic dose in HD homozygotes. Recently, an amino terminal fragment of mutant huntingtin has been found to form self-initiated fibrillar aggregates in vitro. We have tested the capacity for aggregation to assess whether this property matches the criteria expected for a fundamental role in HD pathogenesis. We find that that in vitro aggregation displays a threshold and progressivity for polyglutamine length remarkably similar to the HD disease process. Moreover, the mutant huntingtin amino terminus is capable of recruiting into aggregates normal glutamine tract proteins, such as the amino terminal segments of both normal huntingtin and of TATA-binding protein (TBP). Our examination of in vivo aggregates from HD post-mortem brains indicates that they contain an amino terminal segment of huntingtin of between 179 and 595 residues. They also contain non-huntingtin protein, as evidenced by immunostaining for TBP. Interestingly, like the in vitro aggregates, aggregates from HD brain display Congo red staining with green birefringence characteristic of amyloid. Our data support the view that the expanded polyglutamine segment confers on huntingtin a new property that plays a determining role in HD pathogenesis and could be a target for treatment. Moreover, the new property might have its toxic consequences by interaction with one or more normal polyglutamine-containing proteins essential for the survival of target neurons.
Similar articles
-
Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis.Hum Mol Genet. 2000 Sep 1;9(14):2175-82. doi: 10.1093/hmg/9.14.2175. Hum Mol Genet. 2000. PMID: 10958656
-
Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein.J Biol Chem. 2012 May 4;287(19):16017-28. doi: 10.1074/jbc.M111.252577. Epub 2012 Mar 20. J Biol Chem. 2012. PMID: 22433867 Free PMC article.
-
Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.Neurobiol Dis. 1999 Oct;6(5):364-75. doi: 10.1006/nbdi.1999.0260. Neurobiol Dis. 1999. PMID: 10527804
-
Polyglutamine pathogenesis.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1005-11. doi: 10.1098/rstb.1999.0452. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434299 Free PMC article. Review.
-
Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1013-9. doi: 10.1098/rstb.1999.0453. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434300 Free PMC article. Review.
Cited by
-
A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.Mol Brain. 2012 Aug 14;5:28. doi: 10.1186/1756-6606-5-28. Mol Brain. 2012. PMID: 22892315 Free PMC article.
-
Structural features and domain organization of huntingtin fibrils.J Biol Chem. 2012 Sep 14;287(38):31739-46. doi: 10.1074/jbc.M112.353839. Epub 2012 Jul 16. J Biol Chem. 2012. PMID: 22801429 Free PMC article.
-
Huntington's disease.Neuromolecular Med. 2003;4(1-2):7-20. doi: 10.1385/NMM:4:1-2:7. Neuromolecular Med. 2003. PMID: 14528049 Review.
-
Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse.J Mol Neurosci. 2007;31(2):139-48. doi: 10.1385/jmn/31:02:139. J Mol Neurosci. 2007. PMID: 17478887
-
Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.BMC Neurosci. 2005 Jan 13;6:1. doi: 10.1186/1471-2202-6-1. BMC Neurosci. 2005. PMID: 15649316 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical